High incidence of point mutations of p53 suppressor oncogene in patients with myelodysplastic syndrome among atomic-bomb survivors: a 10-year follow-up.
Imamura
N
N
Abe
K
K
Oguma
N
N
D019943:Amino Acid Substitution; D000753:Anemia, Refractory / Q000209:etiology / Q000235:genetics; D000754:Anemia, Refractory, with Excess of Blasts / Q000209:etiology / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D015331:Cohort Studies; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D015994:Incidence; D007621:Karyotyping; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology / Q000209:etiology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009190:Myelodysplastic Syndromes / Q000209:etiology / Q000235:genetics*; D009689:Nuclear Warfare; D017354:Point Mutation; D011289:Preleukemia / Q000209:etiology / Q000235:genetics; D017741:Survivors